Nautilus Biotechnology (NAUT) vs Precipio (PRPO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Precipio (PRPO) over the past year, gaining 101.8% versus a gain of 26.4%. Over five years, PRPO leads with a -54.7% price change compared with -68.1% for NAUT. Nautilus Biotechnology is the larger company by market cap ($294.6 million vs $42.0 million), about 7.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | PRPO |
|---|---|---|
| Share price | $2.32 | $23.47 |
| Market cap | $294.60M | $42.02M |
| 1-day change | +27.20% | +1.21% |
| YTD return | -6.67% | +0.91% |
| 1-year return | +101.77% | +26.38% |
| 5-year return | -68.13% | -54.71% |
| Forward P/E | — | 60.18 |
| EPS (TTM) | $-0.45 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.31 | $33.63 |
| 52-week low | $0.82 | $16.40 |
| Distance from 52-week high | -46.29% | -30.21% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +65.44% | — |
| Average volume | 2.66M | 127.60K |
| Shares outstanding | 127.26M | 1.79M |
| Employees | 127 | 61 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nautilus Biotechnology is about 7.0 times larger than Precipio by market value ($294.60M vs $42.02M).
- NAUT has outperformed PRPO by 75.4 percentage points over the past year.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
About Precipio
PRPO stock →Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees
NAUT vs PRPO FAQ
Which is bigger, Nautilus Biotechnology or Precipio?
Nautilus Biotechnology (NAUT) is larger, with a market capitalization of $294.60M compared with $42.02M for Precipio (PRPO).
Which stock has performed better over the past year, NAUT or PRPO?
NAUT returned +101.77% over the past 12 months, compared with +26.38% for PRPO (price return, excluding dividends). Past performance does not predict future results.
Are Nautilus Biotechnology and Precipio in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.